AI and Value-Based Care: Machine Learning’s Potential in Reducing Healthcare Waste

By Michael Awood

October 8, 2023

According to a new study, the United States wastes $1 trillion a year on healthcare. The staggering cost of inefficiency is higher than the world’s 17th-biggest country’s GDP. Waste in healthcare affects patient care, the speed of organisations, and the cost of materials. Mistakes and wasteful spending are more likely in the healthcare system due to its complexity. This severely reduces the effectiveness of treatment.

Value-based care methods were created to deal with this issue. They promote cost-effective clinical results that lead to high-quality care at a fair price. In a data-rich environment, making decisions can become too complicated. These things cause mistakes, which make it harder to get high-value care, which wastes more time and money.

Putting this in perspective, about 80,000 people die every year in the US because of inaccurate outcomes. Even with the most up-to-date training and tools, healthcare still has problems. Maintaining awareness of the growing amount of medical info requires a lot of mental effort.

With the help of Machine Learning, both the number of mistakes and the amount of resources used could go down. Algorithms can now be used to make diagnoses instead of the human equivalent, i.e: radiologists, pathologists, and doctors. By using automations such as event reporting, you can keep patients safe. Putting together local, real-time data from institutions and social media could help with public health management and change how we predict future epidemics.

ML might be able to make personalised treatment plans for each patient based on genetic information, clinical presentation factors, and information about the patient’s past. This means that patients get more personalised care, go through fewer therapies that are unsuccessful, and have better overall outcomes.

But these changes also bring about new problems. Problems exist with both the quality of the data and our ability to understand the data that machines create. Accountability for mistakes and bad outcomes, as well as protecting patients’ privacy, are challenging.

Rising healthcare costs not only hurt countries in significant amounts, but they also threaten the foundations of value-based medicine. When it comes to keeping our healthcare system safe, ML shows itself to be a strong tool with immense potential. While there isn’t a guaranteed way to make healthcare better without also making it more efficient, ML shows promise in this area.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.